Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study

Open access
Mehta, Neil, Guy, Jennifer, Frenette, Catherine T., Dodge, Jennifer L., Osorio, Robert W., Minteer, William B., Roberts, John P., Yao, Francis Y. · 2018 · Clinical Gastroenterology and Hepatology

Abstract

BACKGROUND & AIMS: Single‐center studies have reported excellent outcomes of patients who underwent liver transplantation for hepatocellular carcinoma (HCC) after successful down‐staging (reduction of tumor burden with local‐regional therapy), but multi‐center studies are lacking. We performed a multi‐center study, applying a uniform down‐staging protocol, to assess outcomes of liver transplantation and performed an intention to treat analysis. We analyzed factors associated with treatment failure, defined as dropout from the liver transplant waitlist due to tumor progression, liver‐related death without transplant, or recurrence of HCC after transplant. METHODS: We performed a retrospective multi‐center study of 187 consecutive adults with HCC enrolled in the down‐staging protocol at 3 liver transplant centers in California (Region 5), from 2002 through 2012. All patients underwent abdominal imaging 1 month after each local‐regional treatment, and at a minimum of once every 3 months. The primary outcome was probability of treatment failure. RESULTS: Liver transplantation was performed after successful down staging in 109 patients (58%). Tumor explant from only 1 patient had poorly differentiated grade and 7 (6.4%) had vascular invasion. Based on Kaplan‐Meier analysis of data collected a median 4.3 years after liver transplantation, 95% of patients would survive 1 year and 80% of patients would survive 5 years; probabilities of recurrence‐free survival were 95% and 87%, respectively. There were no center‐specific differences in survival in the intention to treat analysis (P = .62), in survival after liver transplantation (P = .95), or in recurrence of HCC (P = .99). Patients were removed from the liver transplantation waitlist due to tumor progression in (n = 59; 32%) or liver‐related death without liver transplantation (n = 9; 5%). Factors associated with treatment failure, based on multivariable analysis, were pre‐treatment levels of alpha‐fetoprotein (AFP) >1000 ng/mL (hazard ratio, 3.3; P < .001) and Child Pugh class B or C (hazard ratio, 1.6; P < .001). The probability of treatment failure at 2 years from the first down‐staging procedure was 100% for patients with levels of AFP >1000 and Child Pugh class B or C vs 29.4% for patients with neither risk factor (P < .001). CONCLUSIONS: In a retrospective, multi‐center study on HCC down staging under a uniform protocol, we found patients to have excellent outcomes following liver transplantation, with no center‐specific effects. Our findings support application of the down‐staging protocol on a broader scale. Patients with Child Pugh class B or C and AFP >1000 are unlikely to benefit from down staging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2017.11.037

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Hepatocellular Carcinoma

    El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529 · cited 3×

    “Fueled by the hepatitis C and fatty liver diseaseepidemics, the incidence of hepatocellular carcinoma (HCC) is projected to increase for at least another decade in the United States.1 With HCC becoming a leading indication for liver transplant (LT),2,3 there have been ongoing efforts by the transplant community to ref…”
    BackgroundInfluential

Cited by

See all 170

Metadata

Authors
Mehta, N., Guy, J., Frenette, C. T., Dodge, J. L., Osorio, R. W., Minteer, W. B., Roberts, J. P., & Yao, F. Y.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2018-06
Volume
16
Issue
6
Pages
955-964
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2770041126
Cited by
170
References
1
FWCI
6.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.